Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs

著录项

• 来源
  《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第null期|共1页
• 作者

  Colclough N.; Ballard P. G.; Barton P.; Chen K.; Cross D. A. E.; Finlay M. R. V.; Han L.; Janefeldt A.; Johnstrom P.; Ward R. A.; Wrigley G. L.; Yana Y.; Yates J. W. T.; Zhang D.; Zhang Z.;

  展开▼
• 作者单位

  AstraZeneca Oncol IMED Macclesfield Cheshire England;

  AstraZeneca Oncol IMED Macclesfield Cheshire England;

  AstraZeneca Oncol IMED Cambridge England;

  AstraZeneca Asia &

  Emerging Markets IMED Shanghai Peoples R China;

  AstraZeneca Oncol IMED Cambridge England;

  AstraZeneca Oncol IMED Cambridge England;

  AstraZeneca Asia &

  Emerging Markets IMED Shanghai Peoples R China;

  AstraZeneca CVMD IMED Gothenburg Sweden;

  Karolinska Inst AstraZeneca Translat Sci Ctr Stockholm Sweden;

  AstraZeneca Oncol IMED Cambridge England;

  AstraZeneca Oncol IMED Cambridge England;

  AstraZeneca Asia &

  Emerging Markets IMED Shanghai Peoples R China;

  AstraZeneca Oncol IMED Cambridge England;

  AstraZeneca Asia &

  Emerging Markets IMED Shanghai Peoples R China;

  AstraZeneca Asia &

  Emerging Markets IMED Shanghai Peoples R China;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学;
• 关键词